{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:29:01Z","timestamp":1791149341611,"version":"4.1.0"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1097\/mol.0b013e3283555a7e","type":"journal-article","created":{"date-parts":[[2012,6,13]],"date-time":"2012-06-13T01:28:17Z","timestamp":1339550897000},"page":"310-320","source":"Crossref","is-referenced-by-count":135,"title":["Gene therapy for lipoprotein lipase deficiency"],"prefix":"10.1097","volume":"23","author":[{"given":"Daniel","family":"Gaudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"M\u00e9thot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"7","key":"R1-7-20211004","first-page":"515","article-title":"Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-355.","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Erratum in: Nat Rev Genet"},{"key":"R2-7-20211004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrg2985","article-title":"Ex vivo gene transfer and correction for cell-based therapies.","volume":"12","author":"Naldini","year":"2011","journal-title":"Nat Rev Genet"},{"key":"R3-7-20211004","first-page":"293","article-title":"Advances in gene delivery systems.","volume":"25","author":"Kamimura","year":"2011","journal-title":"Pharmaceut Med"},{"key":"R4-7-20211004","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"R5-7-20211004","doi-asserted-by":"crossref","first-page":"13226","DOI":"10.1074\/jbc.C000883200","article-title":"Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty.","volume":"276","author":"Tagalakis","year":"2001","journal-title":"J Biol Chem"},{"key":"R6-7-20211004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides.","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R7-7-20211004","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/mt.2011.294","article-title":"Action and reaction: the biological response to siRNA and its delivery vehicles.","volume":"20","author":"Kanasty","year":"2012","journal-title":"Mol Ther"},{"key":"R8-7-20211004","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/clp.11.59","article-title":"Therapeutic potential of antisense oligonucleotides for the management of dyslipidemia.","volume":"6","author":"Crooke","year":"2011","journal-title":"Clin Lipidol"},{"key":"R9-7-20211004","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"R10-7-20211004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2217\/clp.10.73","article-title":"Gene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategies.","volume":"5","author":"Kassim","year":"2010","journal-title":"Clin Lipidol"},{"key":"R11-7-20211004","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/ng0494-335","article-title":"Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia.","volume":"6","author":"Grossman","year":"1994","journal-title":"Nat Genet"},{"key":"R12-7-20211004","doi-asserted-by":"crossref","first-page":"e13424","DOI":"10.1371\/journal.pone.0013424","article-title":"Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis.","volume":"5","author":"Kassim","year":"2010","journal-title":"PLoS One"},{"key":"R13-7-20211004","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0022-2275(20)37569-6","article-title":"Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis.","volume":"37","author":"Goldberg","year":"1996","journal-title":"J Lipid Res"},{"key":"R14-7-20211004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MOL.0b013e3283471972","article-title":"Genetic bases of hypertriglyceridemic phenotypes.","volume":"22","author":"Johansen","year":"2011","journal-title":"Curr Opin Lipidol"},{"key":"R16-7-20211004","first-page":"249","article-title":"Chylomicronemia syndrome.","volume":"37","author":"Chait","year":"1992","journal-title":"Adv Intern Med"},{"key":"R17-7-20211004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0889-8529(05)70025-6","article-title":"The familial chylomicronemia syndrome.","volume":"27","author":"Santamarina-Fojo","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R18-7-20211004","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","article-title":"Etiology and risk of lactescent plasma and severe hypertriglyceridemia.","volume":"5","author":"Tremblay","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R19-7-20211004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MOL.0b013e3283319a1d","article-title":"Severe hypertriglyceridemia and pancreatitis: presentation and management.","volume":"20","author":"Ewald","year":"2009","journal-title":"Curr Opin Lipidol"},{"key":"R20-7-20211004","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/FPC.0b013e328340095e","article-title":"Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics.","volume":"20","author":"Brisson","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R21-7-20211004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosissup.2010.03.004","article-title":"Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.","volume":"11","author":"Gaudet","year":"2010","journal-title":"Atheroscler Suppl"},{"key":"R23-7-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.12.027","article-title":"The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight.","volume":"211","author":"Dallinga-Thie","year":"2010","journal-title":"Atherosclerosis"},{"key":"R24-7-20211004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.07.019","article-title":"Apolipoprotein A-V; a potent triglyceride reducer.","volume":"219","author":"Nilsson","year":"2011","journal-title":"Atherosclerosis"},{"key":"R25-7-20211004","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1194\/jlr.R018689","article-title":"GPIHBP1, an endothelial cell transporter for lipoprotein lipase.","volume":"52","author":"Young","year":"2011","journal-title":"J Lipid Res"},{"key":"R26-7-20211004","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/ng.628","article-title":"Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia.","volume":"42","author":"Johansen","year":"2010","journal-title":"Nat Genet"},{"key":"R27-7-20211004","first-page":"D388","article-title":"Lipoprotein lipase: physiology, biochemistry, and molecular biology.","volume":"6","author":"Goldberg","year":"2001","journal-title":"Front Biosci"},{"key":"R28-7-20211004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1093-3263(00)00096-6","article-title":"Structure-function analysis of D9N and N291S mutations in human lipoprotein lipase using molecular modelling.","volume":"19","author":"Razzaghi","year":"2001","journal-title":"J Mol Graph Model"},{"key":"R29-7-20211004","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1089\/hum.2005.16.1276","article-title":"Gene therapy for lipoprotein lipase deficiency: working toward clinical application.","volume":"16","author":"Rip","year":"2005","journal-title":"Hum Gene Ther"},{"key":"R30-7-20211004","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1161\/01.ATV.0000219283.10832.43","article-title":"Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation.","volume":"26","author":"Rip","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R31-7-20211004","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2004.15.906","article-title":"Long-term correction of murine lipoprotein lipase deficiency with AAV1-mediated gene transfer of the naturally occurring LPL(S447X) beneficial mutation.","volume":"15","author":"Ross","year":"2004","journal-title":"Hum Gene Ther"},{"key":"R32-7-20211004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1089\/hum.2006.17.487","article-title":"Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation.","volume":"17","author":"Ross","year":"2006","journal-title":"Hum Gene Ther"},{"key":"R33-7-20211004","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1161\/ATVBAHA.108.175620","article-title":"Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients.","volume":"28","author":"Stroes","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R34-7-20211004","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2008-07-167510","article-title":"AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells.","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"R36-7-20211004","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Gene therapy with alipogene tiparvovec results in enhanced postprandial clearance of chylomicrons in LPLD patients.","volume":"97","author":"Carpentier","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-7-20211004","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/00007890-200208270-00013","article-title":"Neo Int-05 Study group. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study.","volume":"74","author":"Sadek","year":"2006","journal-title":"Transplantation"},{"key":"R38-7-20211004","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1111\/j.1365-2516.2011.02646.x","article-title":"Challenges of rare disease research: limited patients and competing priorities.","volume":"18","author":"Ragni","year":"2012","journal-title":"Haemophilia"},{"key":"R39-7-20211004","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/187221412799015245","article-title":"Present and future of adeno associated virus based gene therapy approaches.","volume":"6","author":"Ortolano","year":"2012","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"R40-7-20211004","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1056\/NEJMra0907180","article-title":"New therapeutic approaches to Mendelian disorders.","volume":"363","author":"Dietz","year":"2010","journal-title":"N Engl J Med"},{"key":"R41-7-20211004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nrg2317","article-title":"The ethics of human gene transfer.","volume":"9","author":"Kimmelman","year":"2008","journal-title":"Nat Rev Genet"},{"key":"R42-7-20211004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/35038533","article-title":"Gene therapy: trials and tribulations.","volume":"1","author":"Somia","year":"2000","journal-title":"Nat Rev Genet"},{"key":"R43-7-20211004","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nrg2971","article-title":"State-of-the-art gene-based therapies: the road ahead.","volume":"12","author":"Kay","year":"2011","journal-title":"Nat Rev Genet"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201208000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T02:36:45Z","timestamp":1633315005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201208000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e3283555a7e","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}